These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18939903)

  • 21. Significant beneficial effect of AT-1 receptor blockers (sartans) in stroke.
    Al-Nimer MS
    Neurosciences (Riyadh); 2012 Jan; 17(1):6-15. PubMed ID: 22246005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?
    Oprisiu-Fournier R; Faure S; Mazouz H; Boutitie F; Serot JM; Achard JM; Godefroy O; Hanon O; Temmar M; Albu A; Strandgaard S; Wang J; Black SE; Fournier A
    Expert Rev Neurother; 2009 Sep; 9(9):1289-305. PubMed ID: 19769445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal and stroke protection in hypertensive patients at CV risk.
    Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036
    [No Abstract]   [Full Text] [Related]  

  • 24. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotection by angiotensin receptor blockers?
    Anderson C
    J Hypertens; 2008 May; 26(5):853. PubMed ID: 18398323
    [No Abstract]   [Full Text] [Related]  

  • 26. Dual renin-angiotensin system blockade and kidney disease.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Pfeffer MA
    J Am Coll Cardiol; 2009 Jul; 54(3):278-9; author reply 279-80. PubMed ID: 19589445
    [No Abstract]   [Full Text] [Related]  

  • 27. [Blood pressure lowering therapy for mild hypertensive patients with a history of stroke].
    Ishikawa E; Ibayashi S
    Nihon Rinsho; 2008 Aug; 66(8):1560-5. PubMed ID: 18700558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure control and prevention of stroke.
    Karthikeyan VJ; Lip GY
    Expert Rev Neurother; 2006 Feb; 6(2):203-12. PubMed ID: 16466300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Onuigbo MA
    Nephrol Dial Transplant; 2010 Apr; 25(4):1344-5. PubMed ID: 20037177
    [No Abstract]   [Full Text] [Related]  

  • 30. ARBs or ACEIs, that is the question.
    Ishigami T; Uchino K; Umemura S
    Hypertens Res; 2006 Nov; 29(11):837-8. PubMed ID: 17345782
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hypertension 2007-2008].
    Chatzikyrkou C; Menne J; Haller H
    Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Angiotensin II-receptor antagonists compared to other antihypertensives: still insufficient evidence for reducing the risk of cerebrovascular incidents].
    Meerum Terwogt JM; Koopmans RP; Roos YB; van Montfrans GA
    Ned Tijdschr Geneeskd; 2008 Jan; 152(2):71-5. PubMed ID: 18265794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stroke in chronic kidney disease: prevention and management.
    Townsend RR
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S11-6. PubMed ID: 18178791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents?
    Armario P; de la Sierra A
    Ther Adv Cardiovasc Dis; 2009 Jun; 3(3):197-204. PubMed ID: 19443514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effects of renin-angiotensin blockade beyond blood pressure control.
    Mancia G; Giannattasio C; Seravalle G; Quarti-Trevano F; Grassi G
    J Hum Hypertens; 2009 Sep; 23(9):570-7. PubMed ID: 19190657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Baweja S; Holt SG; McMahon LP
    Nephrol Dial Transplant; 2011 May; 26(5):1752-3; author reply 1753. PubMed ID: 21471329
    [No Abstract]   [Full Text] [Related]  

  • 40. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.